Virta Health is a technology company.
Virta Health has raised $305.0M across 4 funding rounds.
Key people at Virta Health.
Virta Health has raised $305.0M in total across 4 funding rounds.
Key people at Virta Health.
Virta Health is a San Francisco-based technology-enabled medical clinic founded in 2014 that provides a clinically proven, virtual treatment to reverse type 2 diabetes and obesity without medications or surgery.[1][3][4] It serves individuals with type 2 diabetes, prediabetes, or obesity, as well as employers, health plans, and healthcare providers, by addressing root causes through personalized nutrition (focusing on carbohydrate restriction and nutritional ketosis), continuous remote care via physician-led teams, health coaches, and AI-driven technology.[1][2][4][5] The company solves the diabetes epidemic—impacting 38 million U.S. adults and costing $586 billion annually—by shifting from symptom management to sustainable reversal, delivering outcomes like 90% average A1c reduction, medication elimination for 7 out of 10 patients, and substantial weight loss, often on a pay-for-success model that aligns incentives with payers.[1][4][7]
Virta's growth momentum is strong, backed by landmark clinical trials showing ~50% diabetes reversal rates in 10 weeks, improvements in biomarkers like BMI and blood pressure, and real-world evidence from over 1 million interactions; it has validated its approach with an impressive portfolio of studies, including a bold guarantee to reduce prescription costs by 70% or forfeit fees.[5][6]
Virta Health was founded in 2014 by Sami Inkinen, a serial entrepreneur who previously co-founded real estate platform Trulia, alongside key experts like Dr. Jeffrey Volek as Chief Science Officer.[3][5][6] Inkinen launched Virta after recognizing the failures of traditional diabetes care—periodic doctor visits and medication reliance—amid the growing epidemic, personally motivated to transform care delivery using technology, AI, and nutritional science to enable continuous, personalized remote treatment.[1][6] Early traction came from clinical evidence demonstrating diabetes reversal through low-carb diets, leading to pivotal moments like the largest type 2 diabetes reversal study and partnerships with employers and health plans on outcome-based pricing.[1][5]
Virta rides the metabolic health revolution, fueled by rising obesity/diabetes rates (109M U.S. adults obese, 79M overweight) and demand for non-pharma solutions amid GLP-1 drug hype, positioning nutrition-tech as a sustainable alternative.[4][7] Timing aligns with virtual care normalization post-pandemic, AI personalization advances, and payer shifts to value-based models, amplified by $586B economic burdens creating tailwinds for cost-saving innovations.[1][4] It influences the ecosystem by pioneering reversal paradigms, validating digital therapeutics via trials, and partnering with employers/health plans to lower costs, challenging pharma dominance and inspiring evidence-driven healthtech.[2][5][6]
Virta's ambitious mission—initially 100M diabetes reversals by 2025, now expanded to 1B for diabetes/obesity—positions it to dominate as metabolic tech scales, especially with GLP-1 integration for weight loss and AI enhancing personalization.[1][4][7] Trends like employer wellness mandates, global diabetes growth (400-500M cases), and outcome-based reimbursement will propel expansion, potentially via deeper enterprise integrations or international reach. Its influence could evolve from niche reverser to standard-of-care setter, saving billions while redefining chronic disease as reversible—proving tech can humanize healthcare at population scale.[1][5][6]
Virta Health has raised $305.0M in total across 4 funding rounds.
Virta Health's investors include Curie.Bio, General Catalyst, Maverick Capital, Operator Partners, Redpoint Ventures, Rock Health, Tiger Global Management, TMV, Town Hall Ventures, Halle Tecco, Jeff Hammerbacher, Vivek Garipalli.
Virta Health has raised $305.0M across 4 funding rounds. Most recently, it raised $130.0M Series E in April 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2021 | $130.0M Series E | Curie.Bio, General Catalyst, Maverick Capital, Operator Partners, Redpoint Ventures, Rock Health, Tiger Global Management, TMV, Town Hall Ventures, Halle Tecco, Jeff Hammerbacher, Vivek Garipalli | |
| Jan 1, 2020 | $93.0M Series C | FJ Labs, Greylock, Harrison Metal, Oceans, Slow Ventures, Unusual Ventures, Venrock, Brad Garlinghouse, Chris Moore, Haroon Mokhtarzada | |
| Apr 1, 2018 | $45.0M Series B | Greylock, Harrison Metal, Venrock, Brad Garlinghouse | |
| Mar 1, 2017 | $37.0M Series A | 75 & Sunny, Greylock, Harrison Metal, SciFi VC, Shasta Ventures, Venrock, Zone 5 Ventures, Barney Harford, Brad Garlinghouse, Gregg Brockway, Greg Slyngstad, Karl Peterson |
